Pathological and molecular diagnosis of triple-negative breast cancer: A clinical perspective

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Penault Llorca, F ^a,b   Viale, G ^c  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Biomarkers; Diagnosis; Molecular; Pathological; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; BEVACIZUMAB; BICALUTAMIDE; BRCA1 PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PANITUMUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST BIOPSY; BREAST CANCER; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL;

EID: 84867120285     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds190     Document Type: Article

References (41)

1. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-321.
2. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
3. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
4. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009; 250: 638-647.
5. Hammond ME, Hayes DF, Dowsett M et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
6. Wolff AC, Hammond ME, Schwartz JN et al. American society of clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
7. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22: 1736-1747.
8. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
9. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25: 3846-3852.
10. Iwamoto T, Booser D, Valero V et al. Estrogen receptor (ER) mRNA and ERrelated gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012; 30: 729-734.
11. Mass R, Corsee S, Charlene K et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials. Proc Am Soc Clin Oncol 2000; 19: Abstr 291.
12. Penault-Llorca F, Bilous M, Dowsett M et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009; 132: 539-548.
13. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20: 1499-1504.
14. Amir E, Clemons M, Freedman OC et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 2010; 28: 15s: Abstr 1007.
15. Broglio K, Moulder SL, Hsu L et al. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. J Clin Oncol 2008; 26 (May 20 Suppl): Abstr 1001.
16. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20: 1953-1958.
17. Pusztai L, Viale G, Kelly CM et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010; 15: 1164-1168.
18. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
19. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011; 16(Suppl 1): 61-70.
20. Weigelt B, Reis-Filho JS. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res 2010; 12 (Suppl 4): S5.
21. Eden P, Ritz C, Rose C et al. 'Good Old' clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004; 40: 1837-1841.
22. Dowsett M, Salter J, Zabaglo L et al. Predictive algorithms for adjuvant therapy: TransATAC. Steroids 2011; 76: 777-780.
23. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
24. Bastien RRL, Ebbert MTW, Boucher KM et al. Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: A direct comparison to oncotype DX. J Clin Oncol 2011; 29(Suppl): Abstr 503.
25. Kelly CM, Bernard PS, Krishnamurthy S et al. Concordance between the 21 gene assay (Oncotype DX®6) and the PAM50 intrinsic classifier for prognosis in early stage ER-positive breast cancer. Ann Oncol 2011; 22(Suppl 2): ii44-ii47: Abstr 82O.
26. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl 1): 1-11.
27. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
28. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
29. Nabholtz J, Weber B, Mouret-Reynier M et al. Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): preliminary results of a multicenter neoadjuvant pilot phase II study. J Clin Oncol 2011; 29 (Suppl): Abstr e11574.
30. Liu D, He J, Yuan Z et al. EGFR expression correlates with decreased diseasefree survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012; 29: 401-405.
31. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26(Suppl): Abstr 1009.
32. O'Shaughnessy J, Weckstein DJ, Vukelja SJ et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Proceedings of the 30th CTRC-AACR San Antonio Breast Cancer Symposium, December 13-16, 2007, San Antonio, TX; AACR Philadelphia, PA: Abstr 308.
33. Baselga J, Gomez P, Awada A et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann Oncol 2011; 21(Suppl 8): Abstr 274O.
34. Niemeier LA, Dabbs DJ, Beriwal S et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-212.
35. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010; 21: 488-492.
36. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008.
37. Traina TA, Feigin K, Patil S et al. Androgen receptor inhibition can stabilize disease in patients with AR(+), ER(-)/PR(-) metastatic breast cancer. Ann Oncol 2009; 20: ii63-ii64: Abstr 192P.
38. Clinical Trials.gov. Bicalutamide in treating patients with metastatic breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00468715 (6 January 2012, date last accessed).
39. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12(Suppl 2): S3.
40. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 1765-1771.
41. Pierga J, Bidard F, Andre F et al. Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1. J Clin Oncol 2011; 29(Suppl): Abstr 10510.